Former Chinese Nationalist Party (KMT) vice chairman Hau Lung-bin (郝龍斌) is to appeal the Food and Drug Administration’s (FDA) authorization of Medigen Vaccine Biologics’ COVID-19 vaccine, he said yesterday.
The administration on July 19 granted Medigen emergency use authorization, even though the drugmaker had not yet completed phase 3 clinical trials.
The government should not authorize the use of a vaccine that has not completed phase 3 trials, Hau said in Taipei on the sidelines of an event to distribute boxed meals with former president Ma Ying-jeou (馬英九) and Broadcasting Corp of China chairman Jaw Shaw-kong (趙少康).
Photo: Fang Pin-chao, Taipei Times
Hau said the government had politicized science in its hasty approval of a domestically developed COVID-19 vaccine.
The emergency use authorization of a vaccine prior to the completion of phase 3 trials is unprecedented, as it means a vaccine’s efficacy has not been verified, he said, adding that President Tsai Ing-wen (蔡英文) and Vice President William Lai (賴清德) have set a poor example in saying they would take the Medigen vaccine.
“The government should spare the lives of the Taiwanese people,” he said.
Minister of Health and Welfare Chen Shih-chung (陳時中), who heads the Central Epidemic Command Center, yesterday said that the center respects the right of citizens to file petitions related to the authorization.
Medigen is the only Taiwanese company to which the FDA has granted emergency use authorization.
The administration said it based its decision on data Medigen obtained in a phase 2 clinical trial of about 4,000 participants earlier this year, which was analyzed through immunobridging and compared with a control group of 200 recipients of the AstraZeneca COVID-19 vaccine in Taoyuan.
Immunobridging is a method to infer the efficacy of a vaccine by comparing the concentration of neutralizing antibodies in each group of recipients with that of an approved vaccine.
Medigen on July 20 announced that it had received permission to conduct a 1,000-person phase 3 clinical trial in Paraguay for its COVID-19 vaccine.
Participants in the trial, to be held with the National University of Asuncion’s medical school, would be recruited in the third quarter of this year and Medigen expects to have interim analysis data in the fourth quarter, the company said.
The trial would compare recipients of the Medigen and AstraZeneca vaccines through immunobridging, it said.
Medigen did not elaborate on its reasons for holding such a small trial or its use of immunobridging, which has been criticized as an insufficient substitute for traditional efficacy data.
Taiwan has agreed to buy 10 million doses of COVID-19 vaccines from two Taiwanese manufacturers: Medigen and United Biomedical, which has not yet been granted emergency use authorization by the FDA.
US climber Alex Honnold is to attempt to scale Taipei 101 without a rope and harness in a live Netflix special on Jan. 24, the streaming platform announced on Wednesday. Accounting for the time difference, the two-hour broadcast of Honnold’s climb, called Skyscraper Live, is to air on Jan. 23 in the US, Netflix said in a statement. Honnold, 40, was the first person ever to free solo climb the 900m El Capitan rock formation in Yosemite National Park — a feat that was recorded and later made into the 2018 documentary film Free Solo. Netflix previewed Skyscraper Live in October, after videos
Starting on Jan. 1, YouBike riders must have insurance to use the service, and a six-month trial of NT$5 coupons under certain conditions would be implemented to balance bike shortages, a joint statement from transportation departments across Taipei, New Taipei City and Taoyuan announced yesterday. The rental bike system operator said that coupons would be offered to riders to rent bikes from full stations, for riders who take out an electric-assisted bike from a full station, and for riders who return a bike to an empty station. All riders with YouBike accounts are automatically eligible for the program, and each membership account
A classified Pentagon-produced, multiyear assessment — the Overmatch brief — highlighted unreported Chinese capabilities to destroy US military assets and identified US supply chain choke points, painting a disturbing picture of waning US military might, a New York Times editorial published on Monday said. US Secretary of Defense Pete Hegseth’s comments in November last year that “we lose every time” in Pentagon-conducted war games pitting the US against China further highlighted the uncertainty about the US’ capability to intervene in the event of a Chinese invasion of Taiwan. “It shows the Pentagon’s overreliance on expensive, vulnerable weapons as adversaries field cheap, technologically
NUMBERs IMBALANCE: More than 4 million Taiwanese have visited China this year, while only about half a million Chinese have visited here Beijing has yet to respond to Taiwan’s requests for negotiation over matters related to the recovery of cross-strait tourism, the Tourism Administration said yesterday. Taiwan’s tourism authority issued the statement after Chinese-language daily the China Times reported yesterday that the government’s policy of banning group tours to China does not stop Taiwanese from visiting the country. As of October, more than 4.2 million had traveled to China this year, exceeding last year. Beijing estimated the number of Taiwanese tourists in China could reach 4.5 million this year. By contrast, only 500,000 Chinese tourists are expected in Taiwan, the report said. The report
RSS